Bone Therapeutics (Belgium) has released its financial results for 2015, which show a solid cash position and promising results in treating Bone conditions in ongoing clinical trials.
This Belgian Biotech is developing cell therapies to treat a bone diseases like osteoporosis with considerable success so far – and 2015 was a year with plenty of important milestones.
These included significant progress in the several clinical trials that Bone Therapeutics is conducting.
ALLOB is an allogeneic cell therapy which has shown a good safety profile. Bone therapeutics has now treated 12 patients (of the expected 18) in its phase IIa trial for spinal fusion, and the therapy was already successful in at least one of the patients.
On the other hand, PREOB (the autologous version of the therapy) is also showing promising results – which could make it a breakthrough therapy for severe osteoporosis.
The safety and cell migration of PREOB is being studied in a phase IIa trial with osteoporosis patients,